Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent HER2-Negative Breast Carcinoma”

194 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 194 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445908
What this trial is testing

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer and HR+/HER2- BC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 175
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT02672475
What this trial is testing

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
Vanderbilt-Ingram Cancer Center 29
Testing effectiveness (Phase 2)Study completedNCT01105312
What this trial is testing

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 28
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Testing effectiveness (Phase 2)Study completedNCT02015559
What this trial is testing

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerOral Complications+5 more
Jonsson Comprehensive Cancer Center 61
Testing effectiveness (Phase 2)UnknownNCT03750396
What this trial is testing

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Who this might be right for
Breast CancerRecurrent Breast CancerStereotactic Body Radiotherapy+3 more
Gangnam Severance Hospital 110
Large-scale testing (Phase 3)Not Yet RecruitingNCT07406542
What this trial is testing

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT00511459
What this trial is testing

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Who this might be right for
Locally Recurrent and Metastatic Breast Cancer
Amgen 228
Large-scale testing (Phase 3)Looking for participantsNCT05861830
What this trial is testing

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Who this might be right for
Advanced Breast Cancer
Peking Union Medical College Hospital 80
Load More Results